SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Höglund Arja) "

Sökning: WFRF:(Höglund Arja)

  • Resultat 1-12 av 12
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Höglund, Arja, et al. (författare)
  • Associations between fluctuations in daytime sleepiness and motor and non-motor symptoms in Parkinson's disease
  • 2021
  • Ingår i: Movement Disorders Clinical Practice. - 2330-1619. ; 8:1, s. 44-50
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract Background Non-motor fluctuations (NMF) are a major concern in Parkinson's disease (PD), and they have been categorised into neuropsychiatric, autonomic and sensory fluctuations. However, this categorisation does not include sleep and sleep-related features, and the association between daytime sleepiness and other motor and/or non-motor fluctuations in PD remains to be elucidated. Objective To investigate the relationship between daytime sleepiness and other non-motor and motor fluctuations in people with PD. Methods A three-day home diary recording daytime sleepiness, mood, anxiety, and motor symptoms was used along with the Karolinska Sleepiness Scale (KSS) and six days of accelerometer (Parkinson's KinetiGraph?; PKG?) registration to detect motor fluctuations among people with a DaTSCAN verified clinical PD diagnosis (32 men; mean PD duration, 8.2?years). Participants were categorised as motor fluctuators or non-fluctuators according to the UPDRS part IV and/or the presence of motor and non-motor fluctuations. Results Fifty-two people with PD participated. Daytime sleepiness correlated significantly with motor symptoms, mood and anxiety among those classified as motor fluctuators (n = 28). Motor fluctuators showed stronger correlations between the individual mean level of all diary variables (daytime sleepiness, anxiety, mood and motor symptoms) when compared to the non-fluctuators (n = 24). Stronger positive within-individual correlations were found among fluctuators in comparison to non-fluctuators. In general, PKG data did not correlate with diary data. Conclusion Episodes of daytime sleepiness, as reported by home diaries, were associated with other self-reported non-motor and motor fluctuations, but were not supported by PKG data.
  •  
2.
  • Hagell, Peter, et al. (författare)
  • Apomorphine formulation influences subcutaneous complications in continuous apomorphine pump therapy for Parkinson’s disease
  • 2017
  • Ingår i: Movement Disorders.
  • Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
    • Objective: To explore if the occurrence and severity of subcutaneous (sc) nodules is influenced by the pharmaceutical formulation of apomorphine used for sc infusion in advanced Parkinson’s disease (PD).Background: Apomorphine infusion is an effective therapy in advanced PD, but a limitation is troublesome sc nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal clinical experience has suggested that shifting from one of these (Apo-Go PumpFill; apoGPF) to another (Apomorphine PharmSwed; apoPS, developed in Sweden) may influence the occurrence and severity of sc nodules.Methods: In this multicenter open-label prospective observational study, 15 people with advanced PD (mean PD- duration, 13.4 years; median Hoehn & Yahr, IV) on apoGPF since a mean of 2.1 years and with troublesome sc nodules were switched to apoPS. Ongoing interventions to treat existing nodules (ultrasound, massage, Hirudoid cream) continued, and apomorphine as well as other drugs was managed according to clinical routines. Data were collected between May 2015 and March 2017; at baseline, at the time of switching (about 2 weeks later), and up to 1.7-4.2 (mean, 2.5) months post-switch follow-up. Primary outcomes were total nodule numbers, size (mm diameter for the 5 worst nodules), consistency (scored 0-3 for the 5 worst nodules), and associated skin changes (scored 0-4 for the 5 worst nodules) and pain (scored 0-5). Patients also rated their perceived PD severity and motor complications (UPDRS IV). Patient preferences 5-12 months post-switch (2-9 months after follow-up) were also recorded.Results: Apomorphine and L-dopa doses did not change over the observation period (P≥0.400). Baseline nodule numbers (7.4 vs. 4.6; P<0.003), size (92.9 vs. 54.1 mm; P=0.016), consistency (11 vs. 5; P=0.003), skin changes (3 vs. 1.5; P=0.205), and average pain (1 vs. 0; P=0.020) improved 11 weeks post-switch. Patient-reported PD severity (P=0.020) and motor fluctuations improved (P=0.051), whereas dyskinesias tended to increase (P=0.205). At 5-12 months post-switch, 13 patients had decided to remain on apoPS; mainly due to improved nodules.Conclusions: These observations suggest that apoPS may have a better safety profile compared to apoGPF in terms of sc nodule occurrence and severity. There is a need for larger, randomized controlled studies for firmer conclusions.
  •  
3.
  • Hagell, Peter, et al. (författare)
  • Apomorphine formulation influences subcutaneous complications in continuous apomorphine pump therapy for Parkinson’s disease
  • 2017
  • Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
    • Objective: To explore if the occurrence and severity of subcutaneous (sc) nodules is influenced by the pharmaceutical formulation of apomorphine used for sc infusion in advanced Parkinson’s disease (PD). Background: Apomorphine infusion is an effective therapy in advanced PD, but a limitation is troublesome sc nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal clinical experience has suggested that shifting from one of these (Apo-Go PumpFill; apoGPF) to another (Apomorphine PharmSwed; apoPS, developed in Sweden) may influence the occurrence and severity of sc nodules. Methods: In this multicenter open-label prospective observational study, 15 people with advanced PD (mean PD- duration, 13.4 years; median Hoehn & Yahr, IV) on apoGPF since a mean of 2.1 years and with troublesome sc nodules were switched to apoPS. Ongoing interventions to treat existing nodules (ultrasound, massage, Hirudoid cream) continued, and apomorphine as well as other drugs was managed accordingto clinical routines. Data were collected between May 2015 and March 2017; at baseline, at the time of switching (about 2 weeks later), and up to 1.7-4.2 (mean, 2.5) months post-switch follow-up. Primary outcomes were total nodule numbers, size (mm diameter for the 5 worst nodules), consistency (scored 0-3 for the 5 worst nodules), and associated skin changes (scored 0-4 for the 5 worst nodules) and pain (scored 0-5). Patients also rated their perceived PD severity and motor complications (UPDRS IV). Patient preferences 5-12 months post-switch (2-9 months after follow-up) were also recorded. Results: Apomorphine and L-dopa doses did not change over the observation period (P≥0.400). Baseline nodule numbers (7.4 vs. 4.6; P<0.003), size (92.9 vs. 54.1 mm; P=0.016), consistency (11 vs. 5; P=0.003), skin changes (3 vs. 1.5; P=0.205), and average pain (1 vs. 0; P=0.020) improved 11 weeks post-switch. Patient-reported PD severity (P=0.020) and motor fluctuations improved (P=0.051), whereas dyskinesias tended to increase (P=0.205). At 5-12 months post-switch, 13 patients had decided to remain on apoPS; mainly due to improved nodules. Conclusions: These observations suggest that apoPS may have a better safety profile compared to apoGPF in terms of sc nodule occurrence and severity. There is a need for larger, randomized controlled studies for firmer conclusions.
  •  
4.
  • Hagell, Peter, et al. (författare)
  • Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
  • 2020
  • Ingår i: Journal of Neurology. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
  • Tidskriftsartikel (refereegranskat)abstract
    • Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
  •  
5.
  • Hagell, Peter, et al. (författare)
  • Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
  • 2020
  • Ingår i: Journal of Neurology. - : D. Steinkopff-Verlag. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
  • Tidskriftsartikel (refereegranskat)abstract
    • Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
  •  
6.
  • Hagell, Peter, et al. (författare)
  • Measuring fatigue in Parkinson's disease : a psychometric study of two brief generic fatigue questionnaires.
  • 2006
  • Ingår i: Journal of Pain and Symptom Management. - : Elsevier. - 0885-3924 .- 1873-6513. ; 32:5, s. 420-32
  • Tidskriftsartikel (refereegranskat)abstract
    • This study evaluated and compared the measurement properties of the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) and the 9-item Fatigue Severity Scale (FSS) in 118 consecutive Parkinson's disease (PD) patients, using traditional and Rasch measurement methodologies. Both questionnaires exhibited excellent data quality and reliability (coefficient alpha>or=0.9), and acceptable rating scale functionality, and both discriminated between fatigued and nonfatigued patients. Factor and Rasch analyses provided general support for unidimensionality of both FACIT-F and FSS, although they do not appear to measure identical aspects of fatigue. No signs of differential item functioning (DIF) were found for the FACIT-F, whereas potential age DIF was detected for two FSS items. These results support the measurement validity of both questionnaires in PD, although the FACIT-F displayed better measurement precision and modest psychometric advantages over the FSS. Availability of psychometrically sound fatigue measures that are applicable across disorders provides a sound basis for advancing the understanding of this common and distressing complaint.
  •  
7.
  • Höglund, Arja, et al. (författare)
  • A 10-year follow-up of excessive daytime sleepiness in Parkinson's disease
  • 2019
  • Ingår i: Parkinson's Disease. - : Hindawi Limited. - 2090-8083 .- 2042-0080. ; 2019
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction. The aim of this prospective study was to investigate excessive daytime sleepiness (EDS) over time and in relation to other PD symptoms among people with Parkinson's disease (PD). Methods. Thirty participants younger than 65 years with PD were randomly selected. At inclusion, mean (SD) disease duration was 6.2 (4.8) years and median (min-max) severity of PD was classified as stage II (stages I-III) according to Hoehn and Yahr. Participants were followed annually for 10 years with clinical assessments of their PD status, medications, comorbidities, and a standardized interview about their sleep habits and occurrence of daytime sleepiness. EDS was assessed by the self-reported Epworth Sleepiness Scale (ESS). Seventeen participants completed the 10-year longitudinal follow-up. Results. Fifteen of 30 persons were classified to suffer from EDS (ESS > 10) at baseline. At the group level, EDS remained stable over 10 years and did not deteriorate in parallel with worsening of motor symptoms. Furthermore,EDS was associated with sleep quality, fatigue, anxiety, depression, and axial/postural/gait impairments. Conclusions. EDS did not worsen over 10 years, although other PD aspects did. EDS in PD seems to be a complex nonmotor symptom that is unrelated to deterioration of motor symptoms in PD.
  •  
8.
  • Höglund, Arja, et al. (författare)
  • Excessive Daytime Sleepiness in Parkinson’s Disease – relationship to motor and non-motor symptoms
  • 2014
  • Konferensbidrag (refereegranskat)abstract
    • Objective: To investigate potential predictors of Excessive daytime sleepiness (EDS) in Parkinson’s disease (PD), and explore how EDS relates to other motor and non-motor PD features.Background: EDS is common in Parkinson’s disease, but its role and relation to other PD features is less well understood.Methods: 118 consecutive persons with PD (54% men; mean age, 64) were assessed regarding EDS using the Epworth Sleepiness Scale (ESS) and a range of motor and non-motor symptoms. Variables significantly associated with ESS scores in bivariate analyses were used in multiple regression analyses with ESS scores as the dependent variable. Principal component analysis (PCA) was conducted to explore the interrelationships between ESS scores and other motor and non-motor PD aspects.Results: Among 114 persons with complete ESS data, significant independent associations were found between ESS scores and axial/postural/gait impairment, depressive symptoms, and pain (R2, 0.199). ESS scores did not load significantly together with any other PD features in the PCA.Conclusions: Only a limited proportion of the variation in EDS could be accounted for by other symptoms, and EDS did not cluster together with any other PD features in PCAs. This suggests that EDS is a separate manifestation differing from e.g. poor sleep quality and fatigue.
  •  
9.
  • Höglund, Arja, et al. (författare)
  • Excessive Daytime Sleepiness in Parkinson’s Disease – relationship to motor and non-motor symptoms
  • 2014
  • Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
    • Objective: To investigate potential predictors of Excessive daytime sleepiness (EDS) in Parkinson’s disease (PD), and explore how EDS relates to other motor and non-motor PD features. Background: EDS is common in Parkinson’s disease, but its role and relation to other PD features is less well understood. Methods: 118 consecutive persons with PD (54% men; mean age, 64) were assessed regarding EDS using the Epworth Sleepiness Scale (ESS) and a range of motor and non-motor symptoms. Variables significantly associated with ESS scores in bivariate analyses were used in multiple regression analyses with ESS scores as the dependent variable. Principal component analysis (PCA) was conducted to explore the interrelationships between ESS scores and other motor and non-motor PD aspects. Results: Among 114 persons with complete ESS data, significant independent associations were found between ESS scores and axial/postural/gait impairment, depressive symptoms, and pain (R2, 0.199). ESS scores did not load significantlytogether with any other PD features in the PCA. Conclusions: Only a limited proportion of the variation in EDS could be accounted for by other symptoms, and EDS did not cluster together with any other PD features in PCAs. This suggests that EDS is a separate manifestation differing from e.g. poor sleep quality and fatigue.
  •  
10.
  • Höglund, Arja, et al. (författare)
  • Like a Wave in Its Variable Shape, Breadth, and Depth : A Qualitative Interview Study of Experiences of Daytime Sleepiness in People with Parkinson's Disease
  • 2022
  • Ingår i: Parkinson's Disease. - : Hindawi Limited. - 2090-8083 .- 2042-0080. ; 2022, s. 1-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Daytime sleepiness is a common nonmotor symptom in Parkinson's disease (PD) which is associated with decreased quality of life and perceived health. However, experiences of daytime sleepiness in people with PD have not been explored. The aim of this qualitative study was to explore experiences of daytime sleepiness in people with PD. Materials and Methods: Five women and seven men (42-82 years) with PD for 1.5 to 21 years and excessive daytime sleepiness (i.e., a score of >10 on the Epworth Sleepiness Scale) participated in the study. Data were collected through individual, semistructured, face-to-face interviews and analyzed with qualitative content analysis. Results: Three themes of the experience of daytime sleepiness were revealed: (1) not an isolated phenomenon, (2) something to struggle against or accept, and (3) something beyond sleepiness.  Conclusion: Daytime sleepiness is a complex nonmotor symptom in PD which manifests itself in several ways. Some experiences are similar, for instance, the attribution of daytime sleepiness to PD and its medical treatment. Differences depend on how sleepiness manifests itself, affects the person, and impacts daily life, as well as whether it causes feelings of embarrassment. Some participants needed to struggle against daytime sleepiness most of the time, and others had found a way to handle it, for example, with physical activity. However, sleepiness may also be used to benefit the person, for example, if they allow themselves to take a power nap to regain energy. The health care professionals can easily underestimate or misinterpret the prevalence and burden of daytime sleepiness because people with PD may describe daytime sleepiness as tiredness, drowsiness, or feeling exhausted, not as sleepiness.
  •  
11.
  • Kautto, Arja, et al. (författare)
  • Taenia lynciscapreoli in semi-domesticated reindeer (Rangifer tarandus tarandus, L.) in Sweden
  • 2022
  • Ingår i: International Journal for Parasitology: Parasites and Wildlife. - : Elsevier BV. - 2213-2244. ; 18, s. 148-151
  • Tidskriftsartikel (refereegranskat)abstract
    • We report here Taenia lynciscapreoli metacestode from the lung lobe of a semi-domesticated reindeer (Rangifer tarandus tarandus). The specimen was detected within a development project concerning remote post mortem inspection at a reindeer abattoir in Sweden. Post mortem inspection was performed according to a routine on-site official meat inspection protocol. The species identification to T. lynciscapreoli was confirmed based on the DNA extracted from the metacestode, which was analysed by sequencing of the cytochrome c oxidase subunit 1. Firstly, our finding shows that semi-domesticated reindeer in addition to several other cervids can act as an additional intermediate host for T. lynciscapreoli. Secondly, it further confirms that this parasite is more widely distributed on the Scandinavian peninsula than what has previously been shown. This is in line with a previous molecular finding of adult T. lynciscapreoli from the Eurasian lynx (Lynx lynx) in Sweden and demonstrates that new intermediate host can be detected. Whether the present finding can be regarded as accidental or have created opportunities for an expansion throughout the northernmost Scandinavian Peninsula remains to be seen.We report here Taenia lynciscapreoli metacestode from the lung lobe of a semi-domesticated reindeer (Rangifer tarandus tarandus). The specimen was detected within a development project concerning remote post mortem inspection at a reindeer abattoir in Sweden. Post mortem inspection was performed according to a routine on-site official meat inspection protocol. The species identification to T. lynciscapreoli was confirmed based on the DNA extracted from the metacestode, which was analysed by sequencing of the cytochrome c oxidase subunit 1. Firstly, our finding shows that semi-domesticated reindeer in addition to several other cervids can act as an additional intermediate host for T. lynciscapreoli. Secondly, it further confirms that this parasite is more widely distributed on the Scandinavian peninsula than what has previously been shown. This is in line with a previous molecular finding of adult T. lynciscapreoli from the Eurasian lynx (Lynx lynx) in Sweden and demonstrates that new intermediate host can be detected. Whether the present finding can be regarded as accidental or have created opportunities for an expansion throughout the northernmost Scandinavian Peninsula remains to be seen.
  •  
12.
  • Vehkala Höglund, Arja (författare)
  • Daytime sleepiness in Parkinson's disease in relation to other symptoms, disease progression and daily life
  • 2020
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • The aim of this doctoral thesis is to explore daytime sleepiness (DS) in Parkinson’s disease (PD). The Papers will evaluate how DS is connected to both motor and non-motor symptoms in PD, changes in DS over time, and the consequences of DS for the daily life of people with PD. Paper I is a multicentre study with 118 participants from four university movement disorder clinics in Sweden. The aims of this study were to (1) explore the relationship between excessive daytime sleepiness (EDS) and other symptoms of PD, and (2) to discover if there are PD symptoms that can predict the prevalence of EDS. Our results showed a weak correlation between EDS and the following: fatigue, depressive and anxiety symptoms, non-specific pain and, axial/postural/gait-related motor symptoms (PIGD phenotype) for people with PD. The factor analysis showed no interrelationship with other symptoms of PD; therefore, EDS seems to be a separate manifestation in PD. Paper II is a longitudinal study with 30 participants younger than 65, from an outpatient hospital clinic in Stockholm, Sweden. The participants were followed for up to 10 years depending on the progression of PD symptoms, especially EDS and other non-motor features. Seventeen participants completed the study. EDS was stable during the follow-up period at the group level but showed variation for individuals from year to year. EDS did not deteriorate in parallel with motor symptoms and disease severity in PD. Paper III is a study about daytime sleepiness and motor and non-motor fluctuations in PD. Fifty-three people with PD who had been investigated with DaTSCAN to verify the PD diagnosis participated in this study. The three-day patient home diary and a six-day actigraphy Parkinson’s KinetiGraphTM (PKG) were used for data collection. The items in the patient home diary were: feeling sleepy; low mood; anxiety and motor symptoms. These conditions correlated with each other and indicated that daytime sleepiness fluctuates with motor and non-motor symptoms in PD, but not with the PKG data. Paper IV is a qualitative study of people with PD and their unique experience of daytime sleepiness and the consequences in their daily life. Twelve people participated in this face- to-face interview study. The impact of daytime sleepiness was not a constant experience but depended on the resilience of the individual and their ability to handle and resist sleepiness. DS could interfere with their daily life by reducing their self-compassion and need to struggle against it. Napping could also be a powerful method for recovery and refreshing the body and brain. In summary, daytime sleepiness is a multi-factorial and multi-dimensional feature in PD. Excessive daytime sleepiness is not a stable phenomenon over time but can vary greatly for individuals from year to year, and did not deteriorate as motor symptoms in PD did. Daytime sleepiness fluctuates with motor and other non-motor symptoms like low mood and anxiety. Personal resilience can affect how people with PD can resist the sleepiness or use the recovery effect of napping to refresh the body and brain during the daytime.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-12 av 12
Typ av publikation
tidskriftsartikel (7)
konferensbidrag (4)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (8)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Höglund, Arja (10)
Hagell, Peter (9)
Fredrikson, Sten (5)
Johansson, Anders (4)
Bergquist, Filip (4)
Willows, Thomas (4)
visa fler...
Johansson, Eva-Lena (4)
Löwed, Berit (4)
Karlberg, Carina (4)
Rådberg, Johan (4)
Dizdar, Nil (3)
Pålhagen, Sven (3)
Hellqvist, Carina (3)
Broman, Jan-Erik (2)
Sorjonen, Kimmo (2)
Hoglund, A. (2)
Hagell, P. (2)
Sjöström, Ann-Christ ... (2)
Lundgren, Maragreth (2)
Sjöström, Anne-Chris ... (2)
Lundgren, Margareth (2)
Svenningsson, P (1)
Johansson, A (1)
Fredrikson, S (1)
Lundgren, M. (1)
Cella, David (1)
Willows, T. (1)
Svenningsson, Per (1)
Sorjonen, K (1)
Grandi, Giulio (1)
Kautto, Arja (1)
Höglund, Johan (1)
Broman, JE (1)
Widner, Håkan (1)
Dizdar, N. (1)
Sandlund, Christina (1)
Palhagen, S (1)
Höglund, A (1)
Östlund, Ulrika, 196 ... (1)
Karlberg, C (1)
Eriksson, Brita (1)
Hagell, Peter, 1966- (1)
Pålhagen, S (1)
Hellqvist, C (1)
Lowed, B (1)
Radberg, J (1)
Bergquist, F (1)
Sjostrom, AC (1)
Johansson, EL (1)
Hellqvist, Carina, 1 ... (1)
visa färre...
Lärosäte
Högskolan Kristianstad (10)
Karolinska Institutet (6)
Uppsala universitet (2)
Örebro universitet (1)
Linköpings universitet (1)
Lunds universitet (1)
visa fler...
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (12)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (10)
Naturvetenskap (1)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy